TXG logo

TXG10x Genomics Inc - Ordinary Shares - Class A

$28.84
$0.21
(0.72%)
Today
Closed $28.84
$0.00
(0.00%)
After Hours
Updated: 04:24 PM EDT
EarningsAug 6
Mkt Cap$3.69B
Vol2.01M
41

Bearish Sentiment

How do you feel about TXG?

News
all
press releases
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
Zacks
News Placeholder
More News
News Placeholder
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group PR Newswire PLEASANTON, Calif., June 9, 2026 Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026...
PR Newswire
News Placeholder
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
Key PointsCEO Serge Saxonov sold 28,893 shares for a total of ~$709,000 across two open-market transactions completed by May 26, 2026...
Nasdaq News: Markets
News Placeholder
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116%
Key PointsQuantedge Capital added 212,600 shares of 10x Genomics in the first quarter; the estimated transaction value was $4.25 million based on quarterly average pricing...
Nasdaq News: Markets
News Placeholder
10x Genomics Q1 Earnings & Revenues Beat Estimates, Gross Margin Up
TXG beats Q1 estimates as consumables growth, margin expansion and lower operating costs narrow losses year over year.
Zacks
News Placeholder
10x Genomics (TXG) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
10x Genomics (TXG) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
News Placeholder
10x Genomics (TXG) Reports Q1 Loss, Beats Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +65.52% and +3.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
10x Genomics Reports First Quarter 2026 Financial Results
10x Genomics Reports First Quarter 2026 Financial Results 10x Genomics Reports First Quarter 2026 Financial Results PR Newswire PLEASANTON, Calif., May 7, 2026 PLEASANTON, Calif., May 7, 2026...
PR Newswire
<
1
2
...
>